Royal Bank of Canada
ELVN icon

Royal Bank of Canada’s Enliven Therapeutics ELVN Stock Holding History

Royal Bank of Canada’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Buy
5,424
+4,205
+345% +$116K ﹤0.01% 4685
2025
Q4 		$18K Sell
1,219
-33,853
-97% -$674K ﹤0.01% 6103
2025
Q3 		$718K Sell
35,072
-32,792
-48% -$661K ﹤0.01% 4224
2025
Q2 		$1.36M Buy
67,864
+62,688
+1,211% +$1.19M ﹤0.01% 3635
2025
Q1 		$102K Buy
+5,176
New +$111K ﹤0.01% 5200
2024
Q4 		– Sell
-3,763
Closed -$96K – 6970
2024
Q3 		$96K Buy
3,763
+380
+11% +$8.8K ﹤0.01% 5373
2024
Q2 		$79K Buy
3,383
+2,254
+200% +$47.4K ﹤0.01% 5405
2024
Q1 		$20K Sell
1,129
-6,862
-86% -$105K ﹤0.01% 5915
2023
Q4 		$110K Buy
7,991
+3,284
+70% +$40.2K ﹤0.01% 5556
2023
Q3 		$65K Buy
4,707
+1,632
+53% +$27.5K ﹤0.01% 5629
2023
Q2 		$63K Buy
3,075
+2,589
+533% +$52.3K ﹤0.01% 5653
2023
Q1 		$11K Buy
486
+339
+231% +$6.89K ﹤0.01% 6260
2022
Q4 		$2K Buy
147
+125
+568% +$2K ﹤0.01% 6923
2022
Q3 		$0 Buy
22
+14
+175% +$83 ﹤0.01% 7542
2022
Q2 		$0 Hold
8
– – ﹤0.01% 7455
2022
Q1 		$0 Hold
8
– – ﹤0.01% 7803
2021
Q4 		$0 Hold
8
– – ﹤0.01% 7716
2021
Q3 		$0 Sell
8
-491
-98% -$10.2K ﹤0.01% 7680
2021
Q2 		$16K Buy
499
+289
+138% +$8.96K ﹤0.01% 6670
2021
Q1 		$7K Buy
210
+108
+106% +$5.49K ﹤0.01% 6932
2020
Q4 		$9K Buy
102
+99
+3,300% +$8.31K ﹤0.01% 6416
2020
Q3 		$0 Buy
+3
New +$271 ﹤0.01% 6699

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada's ELVN Position: Q1 2026 in Review

Royal Bank of Canada increased its Enliven Therapeutics (ELVN) stake by 345% in Q1 2026, buying an estimated $116K and bringing the position to 5,424 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #4685.

Royal Bank of Canada first reported a position in ELVN in Q3 2020 and has held it in 22 quarters since. The position peaked at $1.36M in Q2 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Royal Bank of Canada held 5,424 shares of Enliven Therapeutics worth $212K as of Q1 2026.
  • Royal Bank of Canada bought 4,205 Enliven Therapeutics shares in Q1 2026, an estimated $116K.
  • Enliven Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4685 holding.
  • Royal Bank of Canada first reported a position in Enliven Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's Enliven Therapeutics position peaked at $1.36M in Q2 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.